Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Bio-Techne Corporation
Bio-Techne Corporation News
Bio-Techne Corporation Quantitative Score
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation Earnings & Revenue
Bio-Techne Corporation Financials
Table Compare
Compare TECH metrics with: | |||
---|---|---|---|
Earnings & Growth | TECH | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | TECH | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | TECH | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | TECH | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Bio-Techne Corporation Income
Bio-Techne Corporation Balance Sheet
Bio-Techne Corporation Cash Flow
Bio-Techne Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Neutral |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Bio-Techne Corporation Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 0.3200 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-08-30 | 0.08 | Quarterly |
2024-05-24 | 0.08 | Quarterly |
2024-02-26 | 0.08 | Quarterly |
2023-11-24 | 0.08 | Quarterly |
2023-09-01 | 0.08 | Quarterly |
Bio-Techne Corporation Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Bio-Techne Corporation Executives
Name | Role |
---|---|
Mr. Kim Kelderman | Chief Executive Officer, President & Director |
Mr. James T. Hippel | Executive Vice President of Finance & Chief Financial Officer |
Mr. William A. Geist | President of Protein Sciences Segment |
Dr. Matthew F. McManus M.D., MBA, Ph.D. | President of Diagnostics & Genomics |
Mr. Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Kim Kelderman | Chief Executive Officer, President & Director | Male | 1967 | 1.06M |
Mr. James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | Male | 1971 | 924.74K |
Mr. William A. Geist | President of Protein Sciences Segment | Male | 1969 | 709.94K |
Dr. Matthew F. McManus M.D., MBA, Ph.D. | President of Diagnostics & Genomics | 1969 | 659.01K | |
Mr. Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | Male | 1975 | 430.77K |
Bio-Techne Corporation Insider Trades
Date | 24 Oct |
Name | KEEGAN JOSEPH D |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1462 |
Date | 24 Oct |
Name | KEEGAN JOSEPH D |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 3511 |
Date | 24 Oct |
Name | VESSEY RUPERT |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1462 |
Date | 24 Oct |
Name | VESSEY RUPERT |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 3511 |
Date | 24 Oct |
Name | Bushman Julie L |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1462 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
24 Oct | KEEGAN JOSEPH D | Director | Acquired | A-Award | 1462 |
24 Oct | KEEGAN JOSEPH D | Director | Acquired | A-Award | 3511 |
24 Oct | VESSEY RUPERT | Director | Acquired | A-Award | 1462 |
24 Oct | VESSEY RUPERT | Director | Acquired | A-Award | 3511 |
24 Oct | Bushman Julie L | Director | Acquired | A-Award | 1462 |